Literature DB >> 18668148

PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Na-Li Jia1, Er-Kang Fei, Zheng Ying, Hong-Feng Wang, Guang-Hui Wang.   

Abstract

OBJECTIVE: Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is a dominant neurodegenerative disorder caused by an expansion of the polyglutamine (polyQ) tract in MJD-1 gene product, ataxin-3 (AT3). This disease is characterized by the formation of intraneuronal inclusions, but the mechanism underlying their formation is still poorly understood. The present study is to explore the relationship between wild type (WT) AT3 and polyQ expanded AT3.
METHODS: Mouse neuroblastoma (N2a) cells or HEK293 cells were co-transfected with WT AT3 and different truncated forms of expanded AT3. The expressions of WT AT3 and the truncated forms of expanded AT3 were detected by Western blotting, and observed by an inverted fluorescent microscope. The interactions between AT3 and different truncated forms of expanded AT3 were detected by immunoprecipitation and GST pull-down assays.
RESULTS: Using fluorescent microscope, we observed that the truncated forms of expanded AT3 aggregate in transfected cells, and the full-length WT AT3 is recruited onto the aggregates. However, no aggregates were observed in cells transfected with the truncated forms of WT AT3. Immunoprecipitation and GST pull-down analyses indicate that WT AT3 interacts with the truncated AT3 in a polyQ length-dependent manner.
CONCLUSION: WT AT3 deposits in the aggregation that was formed by polyQ expanded AT3, which suggests that the formation of AT3 aggregation may affect the normal function of WT AT3 and increase polyQ protein toxicity in MJD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668148      PMCID: PMC5552588          DOI: 10.1007/s12264-008-0326-9

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  34 in total

1.  Machado-Joseph disease gene product identified in lymphocytes and brain.

Authors:  G Wang; K Ide; N Nukina; J Goto; Y Ichikawa; K Uchida; T Sakamoto; I Kanazawa
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

2.  Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities.

Authors:  Fusheng Li; Todd Macfarlan; Randall N Pittman; Debabrata Chakravarti
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

3.  An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils.

Authors:  A E Bevivino; P J Loll
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

4.  Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3.

Authors:  Erkang Fei; Nali Jia; Tao Zhang; Xiaochuan Ma; Hongfeng Wang; Chao Liu; Wei Zhang; Lili Ding; Nobuyuki Nukina; Guanghui Wang
Journal:  Biochem Biophys Res Commun       Date:  2007-04-04       Impact factor: 3.575

5.  Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.

Authors:  K Nishiyama; S Murayama; J Goto; M Watanabe; H Hashida; S Katayama; Y Nomura; S Nakamura; I Kanazawa
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

6.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

7.  Polyglutamine protein aggregation and toxicity are linked to the cellular stress response.

Authors:  K J Cowan; M I Diamond; W J Welch
Journal:  Hum Mol Genet       Date:  2003-06-15       Impact factor: 6.150

8.  Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.

Authors:  Bernd O Evert; Ina R Vogt; Ana M Vieira-Saecker; Lucia Ozimek; Rob A I de Vos; Ewout R P Brunt; Thomas Klockgether; Ullrich Wüllner
Journal:  J Neuropathol Exp Neurol       Date:  2003-10       Impact factor: 3.685

9.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

Authors:  Wen Yang; John R Dunlap; Richard B Andrews; Ronald Wetzel
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

10.  Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features.

Authors:  A Dürr; G Stevanin; G Cancel; C Duyckaerts; N Abbas; O Didierjean; H Chneiweiss; A Benomar; O Lyon-Caen; J Julien; M Serdaru; C Penet; Y Agid; A Brice
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

View more
  4 in total

Review 1.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

2.  Mouse ataxin-3 functional knock-out model.

Authors:  Pawel M Switonski; Agnieszka Fiszer; Katarzyna Kazmierska; Maciej Kurpisz; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Neuromolecular Med       Date:  2010-10-14       Impact factor: 3.843

3.  PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates.

Authors:  Hong-Wei Yue; Jun-Ye Hong; Shu-Xian Zhang; Lei-Lei Jiang; Hong-Yu Hu
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

4.  Normal ATXN3 Allele but Not CHIP Polymorphisms Modulates Age at Onset in Machado-Joseph Disease.

Authors:  Marcondes C França; Vanessa E Emmel; Anelyssa D'Abreu; Cláudia V Maurer-Morelli; Rodrigo Secolin; Luciana Cardoso Bonadia; Marilza Santos da Silva; Anamarli Nucci; Laura Bannach Jardim; Maria Luiza Saraiva-Pereira; Wilson Marques; Henry Paulson; Iscia Lopes-Cendes
Journal:  Front Neurol       Date:  2012-11-19       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.